PHASE I STUDY OF OMBRABULIN IN COMBINATION WITH CISPLATIN (CDDP) ADMINISTERED EVERY 3 WEEKS TO JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Takahashi, S.
Ura, T. [1 ]
Nakano, K.
Chin, K.
Yokoyama, M.
Hatake, K.
Yokota, T. [1 ]
Shitara, K. [1 ]
Muro, K. [1 ]
Aoyama, T.
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [11] A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors
    Jérôme Alexandre
    Carmen Kahatt
    Frédérique Bertheault-Cvitkovic
    Sandrine Faivre
    Stephen Shibata
    Werner Hilgers
    François Goldwasser
    François Lokiec
    Eric Raymond
    Garry Weems
    Ajit Shah
    John R. MacDonald
    Esteban Cvitkovic
    Investigational New Drugs, 2007, 25 : 453 - 462
  • [12] A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors
    Alexandre, Jerome
    Kahatt, Carmen
    Bertheault-Cvitkovic, Frederique
    Faivre, Sandrine
    Shibata, Stephen
    Hilgers, Werner
    Goldwasser, Francois
    Lokiec, Francois
    Raymond, Eric
    Weems, Garry
    Shah, Ajit
    MacDonald, John R.
    Cvitkovic, Esteban
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (05) : 453 - 462
  • [13] A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors
    Rasschaert, Marika
    Schrijvers, Dirk
    Van den Brande, Jan
    Dyck, Joke
    Bosmans, Johan
    Merkle, Karlheinz
    Vermorken, Jan B.
    ANTI-CANCER DRUGS, 2007, 18 (05) : 587 - 595
  • [14] A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
    Werner Hilgers
    Sandrine Faivre
    Stéphanie Chieze
    Jérôme Alexandre
    François Lokiec
    François Goldwasser
    Eric Raymond
    Carmen Kahatt
    Abdelkrim Taamma
    Garry Weems
    John R. MacDonald
    Jean-Louis Misset
    Esteban Cvitkovic
    Investigational New Drugs, 2006, 24 : 311 - 319
  • [15] A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
    Hilgers, Werner
    Faivre, Sandrine
    Chieze, Stephanie
    Alexandre, Jerome
    Lokiec, Francois
    Goldwasser, Francois
    Raymond, Eric
    Kahatt, Carmen
    Taamma, Abdelkrim
    Weems, Garry
    MacDonald, John R.
    Misset, Jean-Louis
    Cvitkovic, Esteban
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (04) : 311 - 319
  • [16] Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
    Sessa, Cristiana
    Del Conte, Gianluca
    Christinat, Alexandre
    Cresta, Sara
    Perotti, Antonella
    Gallerani, Elisa
    Lardelli, Pilar
    Kahatt, Carmen
    Alfaro, Vicente
    Iglesias, Jorge L.
    Fernandez-Teruel, Carlos
    Gianni, Luca
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1236 - 1243
  • [17] Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
    Cristiana Sessa
    Gianluca Del Conte
    Alexandre Christinat
    Sara Cresta
    Antonella Perotti
    Elisa Gallerani
    Pilar Lardelli
    Carmen Kahatt
    Vicente Alfaro
    Jorge L. Iglesias
    Carlos Fernández-Teruel
    Luca Gianni
    Investigational New Drugs, 2013, 31 : 1236 - 1243
  • [18] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    Lockhart, A. Craig
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Wang-Gillam, Andrea
    Moseley, Jennifer L.
    Barber, Stephanie L.
    Lane, Alex R.
    Wack, Claudine
    Kassalow, Laurent
    Dedieu, Jean-Francois
    Mita, Alain C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245
  • [19] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    A. Craig Lockhart
    Shankar Sundaram
    John Sarantopoulos
    Monica M. Mita
    Andrea Wang-Gillam
    Jennifer L. Moseley
    Stephanie L. Barber
    Alex R. Lane
    Claudine Wack
    Laurent Kassalow
    Jean-François Dedieu
    Alain C. Mita
    Investigational New Drugs, 2014, 32 : 1236 - 1245
  • [20] A phase I and pharmacokinetic study of the vascular disrupting agent AVE8062 in combination with docetaxel, administered once every 3 weeks to patients with advanced solid tumors
    Tresca, Patricia
    Tosi, Diego
    Van Doorn, Leni
    Fontaine, Helene
    Van der Gaast, Ate
    Veyrat-Follet, Christine
    Oprea, Carina
    Dieras, Veronique
    Eskens, Ferry Alm
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
12345